Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PPP5C | P53041 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PPP2CA | P67775 | 1/20 | 0.44 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.44 |
| ▸ | NPY4R | P50391 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19369982 | 1.00 | HTT (0.53) | HTTLMNAPPP5CALDH1A1KDM4E | |
| SCHEMBL20199815 | 1.00 | HTT (0.53) | HTTLMNAPPP5CALDH1A1KDM4E | |
| SCHEMBL25724424 | 0.88 | HTT (0.52) | HTTLMNAPPP5CALDH1A1KDM4E | |
| SCHEMBL14233304 | 0.88 | HPGD (0.48) | — | |
| SCHEMBL10015708 | 0.88 | HTT (0.47) | HTTLMNA | |
| SCHEMBL8261299 | 0.88 | HTT (0.47) | HTTLMNA | |
| SCHEMBL15014605 | 0.83 | ALDH1A1 (0.43) | ALDH1A1 | |
| SCHEMBL29008786 | 0.83 | JAK1 (0.44) | — | |
| SCHEMBL26615251 | 0.83 | JAK1 (0.44) | — | |
| SCHEMBL15014480 | 0.83 | ALDH1A1 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS INC (US) | 2009-06-18 | — | — | US | disclosed |
| US-7405194-B2 | Therapeutic agents and methods of use thereof for the treatment of melanoma | PRAECIS PHARMACEUTICALS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| WO-2008066641-A2 | METHODS FOR TREATING MITF ASSOCIATED DISEASES BY THE USE OF METHIONINE AMINOPEPTIDASE-2 INHIBITORS | PRAECIS PHARMACEUTICALS INCORPORATED (US) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156624-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | HTT 4314/4885LMNA 4052/4885PPP5C 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.